Sampaio Filipe, Marrinhas Carla, Fonte-Oliveira Luísa, Marcos Ricardo, Oliveira Pedro N, Santos Marta
Cytology and Hematology Diagnostic Services, Laboratory of Histology and Embryology, Department of Microscopy, ICBAS-School of Medicine and Biomedical Sciences, University of Porto (U.Porto), Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal.
CEDIVET-Laboratório Clínico Veterinário, 4465-671 Leça do Balio, Portugal.
Vet Sci. 2025 Jun 8;12(6):561. doi: 10.3390/vetsci12060561.
Canine lymphoma (CL) is a heterogeneous neoplasm with varying prognoses, and Ki67 expression is a key marker for assessing tumor proliferation. This study aimed to compare Ki67 immunostaining in cytology smears (PSCS) and cell blocks (CBs) of canine lymphoma cases. Ki67 immunostaining was performed on 30 cases (26 nodal and 4 non-nodal) of CL, including B-cell, T-cell, and null-phenotype lymphomas. The Ki67 index was quantified manually using image analysis software as a support. The results showed Ki67 positivity in all CBs, with archival time affecting the antigenicity in PSCS, especially in samples older than two years. The Ki67 index in CBs of nodal CL were higher, and there was no significant agreement on Ki67 classification in PSCS and CBs. A univariate brief survival analysis was performed to preliminary evaluate the prognostic value of Ki67 in cytological samples. Ki67 indexes determined in cytology showed no significant association with survival. Cases of nodal CL with high Ki67 in CBs, if treated with chemotherapy, tended to survived longer (compared to those animals not treated with chemotherapy). These preliminary results showed that Ki67 immunostaining in CBs is more reliable for assessing CL proliferation and might offer predictive information. These findings highlight the potential of Ki67 quantification in CBs for supporting treatment decisions.
犬淋巴瘤（CL）是一种预后各异的异质性肿瘤，Ki67表达是评估肿瘤增殖的关键标志物。本研究旨在比较犬淋巴瘤病例细胞学涂片（PSCS）和细胞块（CBs）中的Ki67免疫染色情况。对30例CL病例（26例淋巴结型和4例非淋巴结型）进行了Ki67免疫染色，包括B细胞、T细胞和无表型淋巴瘤。使用图像分析软件辅助手动定量Ki67指数。结果显示所有CBs中Ki67均呈阳性，存档时间影响PSCS中的抗原性，尤其是在保存超过两年的样本中。淋巴结型CL的CBs中Ki67指数较高，PSCS和CBs中Ki67分类无显著一致性。进行单因素短期生存分析以初步评估Ki67在细胞学样本中的预后价值。细胞学检测确定的Ki67指数与生存无显著相关性。CBs中Ki67高表达的淋巴结型CL病例，若接受化疗，生存期往往更长（与未接受化疗的动物相比）。这些初步结果表明，CBs中的Ki67免疫染色在评估CL增殖方面更可靠，可能提供预测信息。这些发现突出了CBs中Ki67定量在支持治疗决策方面的潜力。
